Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
HUTCHMED (China) Limited American Depositary Shares logo

NASDAQ · HCM

HUTCHMED (China) Limited American Depositary Shares

Healthcare · Drug Manufacturers - Specialty & Generic

$13.15

Down-$0.44 (-3.24%)

Updated Oct 31, 2026, 3:06 AM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.39B
P/E ratio
5.13
Dividend yield
0.00%
52-week range
$9.77 – $16.33
Volume
33.49K
Avg. volume
38.74K

Price performance · HCM

HCM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

HCM closed at $13.15 after 21 trading sessions, down 7.39% for the selected period.

Last close
$13.15
Period change
-7.39%
Period low
$13.15
Period high
$14.74
Daily close
View OHLC price history
HCM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$13.35$13.415$13.14$13.1533.49K
Oct 29, 2026$13.36$13.67$13.36$13.5934.28K
Oct 28, 2026$13.45$13.49$13.12$13.3237.38K
Oct 27, 2026$14.10$14.10$13.52$13.8051.51K
Oct 26, 2026$14.34$14.42$14.25$14.2719.14K
Oct 23, 2026$14.36$14.80$14.26$14.3623.39K
Oct 22, 2026$14.26$14.46$14.22$14.2823.36K
Oct 21, 2026$14.70$14.74$14.37$14.3772.37K
Oct 20, 2026$14.69$14.94$14.62$14.7450.93K
Oct 19, 2026$14.08$14.40$14.01$14.1828.37K
Oct 16, 2026$14.15$14.28$14.05$14.0522.41K
Oct 15, 2026$13.52$13.95$13.52$13.9451.86K
Oct 14, 2026$13.51$13.99$13.465$13.4881.77K
Oct 13, 2026$13.52$13.58$13.28$13.5037.01K
Oct 12, 2026$14.00$14.00$13.58$13.6843.78K
Oct 9, 2026$13.74$14.10$13.74$14.1050.07K
Oct 8, 2026$13.87$13.87$13.51$13.6745.08K
Oct 7, 2026$14.29$14.35$14.06$14.2858.04K
Oct 6, 2026$14.55$14.745$14.54$14.6068.47K
Oct 5, 2026$14.14$14.34$13.90$14.3165.11K
Oct 2, 2026$14.31$14.34$14.10$14.2045.74K

Latest HCM news

The latest Smart Investors Daily articles mentioning HCM.

Stock researchCompany · Overview

HCM research

Overview

Company profile and research snapshot.

Company profile

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$17.50
Implied upside
—
Analysts
27
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will ta

Yahoo · Oct 26, 2026

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population — — Offers a potential new standard of care through an all-oral, biomarker-driven frontline strategy for MET-overexpressing, EGFR-mutated lung cancer patients — HONG KONG, SHANGHAI and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By